Vascular endothelial growth factor receptor (VEGFR) 3 is a transmembrane receptor tyrosine kinase that is activated by its ligands VEGF-C and VEGF-D. Although VEGFR-3 has primarily been linked to the regulation of lymphangiogenesis, we demonstrate here a role for VEGFR-3 in megakaryopoiesis. 2
Introduction
VEGFR-3 is a member of the VEGFR receptor tyrosine kinase family. It is expressed on lymphatic endothelial cells (LECs) and plays a central role in the regulation of lymphangiogenesis. 1 Upon binding to its ligands VEGF-C and VEGF-D, VEGFR-3 is activated, and orchestrates the outgrowth of lymphatic vessels. 1 While the role of VEGFR-3 in regulating lymphangiogenesis is well established 1 , several lines of evidence suggest that in addition to being involved in the regulation of lymphangiogenesis, VEGFR-3 may also play a role during hematopoiesis. Targeted deletion of VEGFR-3 in mice results in defective definitive hematopoiesis. 2 Furthermore, VEGFR-3 is also expressed in CD14 + monocytes 3, 4 and circulating CD34 + endothelial precursors 5 . Moreover, VEGFR-3 is expressed in human leukemia 6 as well as certain leukemic cell lines [7] [8] [9] . Indeed, VEGFR-3 was first identified in HEL cells. 7 With these observations in mind, we investigated whether VEGFR-3 plays a role during hematopoiesis, and found that VEGFR-3 is expressed on megakaryocyte precursor cells in the bone marrow.
During murine hematopoiesis, Sca-1+ hematopoietic stem cells give rise to the precursors of all hematopoietic lineages. 10 Megakaryocytes develop from CD34 + progenitors. 11, 12 Proliferation and differentiation of megakaryocyte progenitors is mainly driven by thrombopoietin (TPO), a key regulator of megakaryopoiesis and thrombopoiesis. 13 Upon induction of differentiation, the progenitors pass through several precursor stages, during which time they change from being CD38 -to CD38 + and finally develop into promegakaryoblasts. 14, 15 The promegakaryoblasts progressively become polyploid as a result of endoreplication and lose expression of CD34. 12 This process results in the development of mature megakaryocytes that produce platelets. 16 While CD41 and CD61 are expressed during all stages of megakaryocytic differentiation from the progenitor through to the mature megakaryocyte 17, 18 , CD42 is expressed slightly later during megakaryopoiesis 12 . All three molecules therefore serve as useful markers of this lineage 15, 19 .
Here we show that VEGFR-3 is expressed on megakaryocyte precursors and during the early endoreplication of promegakaryoblasts, but is not present on mature megakaryocytes. Accordingly, specific activation of VEGFR-3 in primary bone marrow cultures impaired the transition to polyploidy of CD41 + cells, whereas treatment with VEGFR-3 blocking antibodies conversely promoted endoreplication. For the specific activation of VEGFR-3, we used a mutant form of VEGF-C 20 that binds only to VEGFR-3 but not VEGFR-2, which is also present on megakaryocytic cells 21 . While treatment of experimental mice with VEGFR-3-specific ligand or blocking antibodies did not significantly alter steady-state megakaryopiesis or thrombopoiesis, VEGFR-3 activation after sub-lethal irradiation significantly increased the numbers of CD41 
Materials & Methods
Cell Culture HEL cells were obtained from DSMZ (Braunschweig, Germany) and cultivated in RPMI (Gibco, Karlsruhe, Germany) containing 10% FCS, 1% penicillin-streptomycin.
Differentiation was induced with 10 nM TPA (Sigma, Taufkirchen, Germany). Primary human microvascular LECs (Cambrex, Verviers, Belgium) from the dermis (HMVECdLyNeo) were cultivated in EGM-2MV (Lonza, Basel, Switzerland), 5% FCS, supplemented with growth factors provided by the manufacturer. Bovine lymphatic endothelial (BLE) cells were cultivated in DMEM (Gibco) containing 20% FCS and 1% penicillin-streptomycin on gelatin-coated plastic. 293 cells were cultivated in DMEM supplemented with 10% FCS and 1% penicillin-streptomycin.
Western blot analysis
Cell lysates were analysed using standard Western blotting techniques. The membranes were probed with antibodies specific for VEGFR-3 (R&D Systems, Wiesbaden, GermanyeBioscience, Frankfurt, Germany), CD31 (Santa Cruz, Heidelberg, Germany), CD34 (DianovaAbcam, HamburgCambridge, GermanyUK), CD42a (Santa Cruz), CD61 (Dako, Hamburg, GermanyR&D Systems), CD144 (Santa Cruz) or GpA (IBGRL, Bristol, UK). Probing with GATA-1HPRT antibodies (Santa Cruz) served as a loading control.
PCR analysis
RNA was prepared using peqGOLD RNAPure (PeqLab, Erlangen, Germany). Synthesis of cDNA using Superscript II (Invitrogen, Karlsruhe, Germany) was performed according to the manufacturer's recommendations. For PCR, cDNAs were amplified as follows: 94°C, 30 seconds, 60°C, 30 seconds and 72°C, 90 seconds (VEGFR-2, Prox1, Lyve1, Podoplanin, hprt, Fli-1, Fog-2, Gata-2 and Elf-1) or 94°C, 30 seconds, 54°C, 30 seconds and 72°C, 90 seconds (VEGFR-3). Details of the primers used are in supplementary Material and Methods.
Tubule formation on collagen gels
Collagen type 1 was prepared from rat tails. Tendons were isolated, dissolved in acetic acid, then filtered, lyophilized and re-dissolved in 0.1% acetic acid at 4 mg/ml. Cells were seeded on collagen gels (2 mg/ml) and cultured in the presence of 30 ng/ml VEGF 165 (Promokine, Heidelberg, Germany) for 8 days. Tubule formation was analysed as previously described.
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IHC
For the immunohistochemical analysis of VEGFR-3 expression in the bone marrow, cryosections of de-calcified murine femurs embedded in tissue freezing medium (Leica, Nussloch, Germany) were fixed in acetone and stained with VEGFR-3 antibodies (eBioscience).
MACS
Bone marrow cells isolated from femurs and tibiae of C57BL/6 mice were treated with Fc-block (Becton Dickinson, Heidelberg, Germany), then incubated with antibodies against VEGFR-3 (R&D Systems, Wiesbaden, Germany), Sca-1, CD41 or CD38 (all Becton Dickinson) followed by specific secondary MACS antibodies (Miltenyi, Bergisch-Gladbach, Germany) according to the manufacturer´s recommendations. Cell populations were then either enriched or depleted for the labelled epitope using LS or LD columns (Miltenyi), respectively. The purity of the sorted populations was controlled by flow cytometry.
CD42 FACS
Bone marrow was isolated from femurs and tibiae of C57BL/6 mice, then stained with antibodies specific for VEGFR-3 (R&D Systems) and/or CD42a (Emfret, Eibelstadt, Germany), and analysed in FACS.
Lethal irradiation and bone marrow transplantation
C57BL/6 mice were irradiated with lethal doses (9 Gy) from a -source. After 24 hours, the mice were all transplanted in parallel by intravenous injection with either complete bone marrow, bone marrow depleted of VEGFR-3 positive cells or bone marrow mock depleted with an appropriate isotype control using MACS as described above. EDTA blood samples were taken from all animals on days 0, 5, 7, 9, 12, 15, 19, 22, 26, 29, 33 and 44 post transplantation, and analysis was performed by a commercial veterinary laboratory (Laboklin, Bad Kissingen, Germany).
Isolation and culture of primary murine bone marrow cells
Bone marrow was isolated from femurs and tibiae of C57BL6 mice. After lysis of red blood cells with ammonium-chloride-potassium (ACK) buffer, the cells were transferred to IMDM (Gibco) supplemented with 1% penicillin/streptomycin, 10% 293 cellconditioned DMEM, Nutridoma SP (Roche, Mannheim, Germany), L-glutamine and 100 pg/ml recombinant murine thrombopoietin (RDI Diagnostics, Concord, USA).
Depending on the experiment the cells were cultured with either 100 µg/ml mF4-31C1 VEGFR-3 blocking antibodies (kindly provided by ImClone Systems, New York, USA), 100 µg/ml of rat IgG isotype control or 400 ng/ml of VEGF-C-Cys, a mutant form of VEGF-C that activates VEGFR-3 but not VEGFR-2 20 . After 72 hours, the medium was renewed, and supplemented with 37 ng/ml thrombopoietin. After a further 72 hours, the cells were harvested, treated with Fc-block (Becton Dickinson), incubated with CD41 antibodies, and fixed in 70% EtOH. Nuclei were stained with Draq5 (Biostatus Ltd, Shepshed, UK), then the cells were analysed using a FACScan cytometer (Becton Dickinson). The bone marrow from each animal was either divided equally, each half receiving either VEGF-C-Cys or control treatment, or undivided bone marrow was used for the treatments (VEGFR-3 blocking). Significance was therefore tested accordingly using two-tailed paired or unpaired t-tests, respectively.
Long-term injections
C57BL/6 mice were injected daily with 25 µg VEGF-C-Cys for three weeks. Blood was taken on days 0, 3, 7, 10, 14, 17 and 21. In the blocking antibody experiments, mice were injected with 600 µg/animal per injection of mF4-31C1 VEGFR-3 blocking antibody, isotype control Ig, or PBS, following a Monday-Wednesday-Friday schedule for six weeks. Blood was taken on days 0, 8, 13, 16, 20, 23, 27 , 30, 34, 37, 41 and 44, and analysed as described above. In each experiment, all animals were treated at the same time and on the same day, and all animals were bled at each time point. At the end of the experiment, bone marrow was isolated from femurs and tibiae, treated with Fc-block (Becton Dickinson), stained with FITC-conjugated anti CD41 antibodies (Becton Dickinson), then fixed in 70% EtOH. Nuclei were stained with Draq5 (Biostatus Ltd, Shepshed, UK), and the number and ploidy of CD41 positive cells was subsequently analysed using a FACScan cytometer (Becton Dickinson). Significance was tested using two-tailed non-paired t-tests, assuming equal variance.
Recovery kinetics after sub-lethal irradiation
Experimental C57BL/6 mice were sub-lethally irradiated (4.5 Gy) in a -source. They were then either injected daily with VEGF-C-Cys (25 µg/animal and injection) or PBS, or were injected with 600 µg/animal per injection of mF4-31C1 VEGFR-3 blocking antibodies, isotype control Ig or PBS every other day intra-peritoneally. Blood was taken on days 0, 7, 11, 14, 18 and 21 post irradiation and analysed as described above. In each experiment, all animals were treated at the same time and on the same day, and all animals were bled at each time point. Bone marrow was isolated from femurs and tibiae 20 days after irradiation, and the number and ploidy of CD41 positive cells in the bone marrow was assessed as described above. Significance was tested using two-tailed nonpaired t-tests, assuming equal variance.
TPO administration
C57BL/6 mice were administered with 5 µg recombinant murine TPO (RDI), followed by daily injections of either 25 µg VEGF-C-Cys or PBS. One group received only PBS throughout. Blood was taken and analysed 0, 3, 5, 7 and 10 days post TPO administration. All animals were treated at the same time and on the same day, and all animals were bled at each time point. After 10 days, the animals were killed and the number and ploidy of CD41 positive cells in the bone marrow was assessed as described above. Significance was tested using two-tailed non-paired t-tests, assuming equal variance. Significance was tested using two-tailed non-paired t-tests, assuming equal variance.
5-FU treatment
All animal experiments were approved by the local authorities, and performed according to the German legal requirements.
Results
Expression of VEGFR-3 and other lymphatic endothelial markers is upregulated upon phorbol diester-induced megakaryocytic differentiation of HEL cells.
VEGFR-3 is widely used as a marker for lymphatic endothelium. Originally, however, the receptor was cloned from the human erythroleukemia cell line HEL. , although we also found that expression of Glycophorin A whose expression is associated, usually correlated with erythroid differentiation, was also found to be increasednot reduced upon TPA-induced megakaryocytic differentiation ( Figure 1B ). S, which is,. hHowever, consistent with previous findings, which show that the Glycophorin A protein is not downregulated upon TPA-induced megakaryocytic differentiation of HEL cells. 24 Uponubsequent to TPA treatment, both adherent and suspension populations of HEL cells were observed that exhibited virtually identical marker profiles and viability. Apart from their adhesive properties and the expression levels of fog-2, which was higher in the adherent population, and CD144, we were unable to distinguish between them (Figure 1 B, C; data not shown).
A survey of the literature revealed that virtually all markers described to date as being expressed on megakaryocytes can also be expressed on endothelial cells (Supplementary To define further the stages of megakaryopoiesis during which VEGFR-3 is expressed, co-stainings with the stem cell marker Sca-1, as well as CD38, CD41 and VEGFR-3 were performed. Expression of Sca-1 is lost during myeloid differentiation. 25 CD38 expression, in turn, is increased early in megakaryopoiesis from the BFU-MK stage on. 26 Finally, CD41 becomes substantially upregulated at the beginning of endoreplication and subsequent polyploidy. 15, 18 The double stainings showed that 1.8% of the Sca- These observations suggested to us that VEGFR-3 might be expressed on hematopoietic stem cells through to the promegakaryoblast stage. However, Sca1 is not only expressed on hematopoietic stem cells but also on the immediate progenitors arising from the stem cells.
27
In order to test whether VEGFR-3 is expressed on hematopoietic stem cells, we transplanted either complete, or VEGFR-3-depleted bone marrow into lethally irradiated mice. The recovery of thrombocytes and erythrocytes was monitored. As expected, circulating platelet counts dropped dramatically the first few days after the irradiation, and later recovered ( Figure 3D ). However, we did not observe any difference in the kinetics of recovery between the groups transplanted with VEGFR-3 depleted bone marrow and the control groups.
Together, these data are consistent with the notion that VEGFR-3 is not expressed on hematopoietic stem cells, but rather on megakaryocyte precursors through to the premegakaryoblast stage, and that VEGFR-3 expression is lost as megakaryocytes further mature. This notion is further substantiated by the observation that VEGFR-3+ bone marrow cells co-express CD42, a marker for megakaryocytes that is not expressed on hematopoietic precursor cells (Supplementary Figure 54) . 28 We also examined whether megakaryocytic lineage cells express LEC markers, similar to the situation in HEL cells. This proved to be the case, as CD41 + cells expressed Lyve-1 (Supplementary Figure 6A5A) , and the majority of VEGFR-3+ bone marrow cells express podoplanin (Supplementary Figure 6B5B) .
Manipulation of VEGFR-3 influences megakaryopoiesis in vitro.
In order to examine the role that VEGFR-3 plays during megakaryopoiesis, we cultivated Our data suggest that the specific activation of VEGFR-3 during megakaryopoiesis impairs the transition to polyploid stages, whereas blocking the receptor promotes differentiation and endoreplication.
Neither activation nor blocking of VEGFR-3 influences steady-state megakaryopoiesis and thrombopoiesis in vivo.
To study potential effects of VEGFR-3 manipulation on megakaryopoiesis and thrombopoiesis in vivo, we first injected VEGF-C-Cys to activate VEGFR-3, or PBS as a control into mice on a daily basis for three weeks. Thrombocyte concentrations in the blood were monitored regularly. After three weeks of treatment, the mice were killed. Thrombocyte homeostasis is tightly controlled in mammals, and alternative mechanisms exist that can compensate for perturbation of particular regulatory pathways. 13 As we observed significant effects of VEGFR-3 manipulation on primary murine bone marrow cells in vitro but not in vivo, we reasoned that this might be due to such compensatory mechanisms. To circumvent this, we manipulated VEGFR-3 activation under conditions in which megakaryopoiesis and thrombopoiesis are stimulated over and above the normal physiological steady-state.
First, we examined whether VEGFR-3 activation affects TPO-induced megakaryopoiesis and thrombopoiesis. Administration of a single dose of TPO leads to a dramatic temporary increase in platelet counts that peaks at day five, then decreases to physiological concentrations within ten days post TPO administration.
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In order to test whether VEGFR-3 activation affects TPO-mediated effects on platelet production, we injected mice with an initial dose of TPO, followed by daily administration of VEGF-CCys. We found that VEGF-C-Cys significantly increased peak platelet counts at day five in comparison with the control group ( Figure 5A ).
In rodents, 5-FU is known to induce thrombocytopenia, followed by pronounced thrombocytosis, which can occur in waves and has been shown to occur independently of TPO. 30 We injected mice with a single dose of 5-FU and the animals were subsequently treated with VEGF-C-Cys. We found that VEGFR-3 activation transiently, but significantly (p<0.002) limited 5-FU-induced thrombocytopenia, as well as thrombocytosis (p=0.005) in comparison with the control group ( Figure 5B) .
Furthermore, VEGFR-3 activation led to a more sustained thrombocytosis compared to the control group (p<0.04) during the second wave of thrombocytosis ( Figure 5B ).
Finally, we sub-lethally irradiated mice to partially destroy the bone marrow, then followed the recovery of CD41 + bone marrow cells. VEGFR-3 activity was manipulated by injecting the mice with either VEGF-C-Cys or VEGFR-3 blocking antibodies.
Thrombocyte numbers were not significantly affected by these treatments (Figure 5 C, F) . 
Discussion
Here we report that in addition to its well-studied expression on LECs, VEGFR-3 is also We found that VEGFR-3 is co-expressed with Sca-1, a marker of hematopoietic stem and precursor cells, and with CD41, a megakaryocytic marker that has also been reported to be expressed by hematopoietic precursor cells with myeloid and lymphoid potential. One reason for this similarity may be a common precursor cell, the hemangioblast, that is believed to give rise to both lineages. Although we cannot completely exclude that the substantial increase in CD41 + cells observed upon VEGFR-3 activation may have balanced out the reduction in polyploid cells and thus kept thrombocyte numbers at similar levels to the controls, these data nevertheless also speak for independent regulation of megakaryopoiesis and thrombopoiesis. This notion is supported by a number of studies that show that TPO levels do not always correspond to platelet counts. 13 The inhibition of the development of polyploidy in CD41 , is found in thrombocytes and is released upon platelet activation 37 , similar to TGF-. TPO and VEGF-C are also both induced by IL-6.
1,38
Notably, both TPO and TGF- levels increase after irradiation 39, 40 , and could therefore also combine with VEGFR-3 activation to exert the effects on megakaryopoiesis we observed here upon sub-lethal irradiation.
VEGFR-3 activation may also act to regulate megakaryocyte differentiation and platelet production independently of TPO. While TPO is the principal regulator of megakaryocytic proliferation and differentiation, other factors such as interleukins can influence megakaryopoiesis and thrombopoiesis. Some of these factors (e.g. probably act indirectly by inducing TPO expression. 13 Nevertheless, targeted deletion of the TPO receptor c-Mpl in mice does not completely destroy megakaryopoiesis and thrombopoiesis 41 indicating additional TPO-independent control mechanisms. It is therefore significant that c-mpl deficient mice respond to 5-FU treatment with marked thrombocytosis, suggesting that 5-FU-induced thrombocytosis is independent of TPO. 30 Our data shows that 5-FU-induced thrombocytosis is significantly impaired by VEGFR-3 activation, suggesting that VEGFR-3 also plays a role in the TPO-independent regulation of thrombocytosis. In this context, VEGFR-3 activation could potentially act by impairing megakaryocytic differentiation, leading to a reduction in thrombocytosis.
Alternatively or in addition, the precursor pool might be expanded, and could potentially contribute to the increased platelet counts we observed during the second wave of thrombocytosis.
VEGFR-3 signalling has been implicated in a number of disease processes, and manipulation of VEGFR-3 activity is a promising therapeutic avenue. 1, 42 Therapeutic activation of VEGFR-3 on LECs has been proposed as a treatment for lymphedema. 1 Conversely, VEGF-C/D-regulated, tumor-induced lymphangiogenesis promotes metastasis, and there has been much interest in the potential of VEGFR-3 blockade as a means of suppressing metastasis in the context of tumors. 42, 43 Potential side effects of the manipulation of VEGFR-3 activity remain to be investigated. The data presented here suggest that altered megakaryopoiesis and platelet production might occur upon VEGFR-3 manipulation, depending on the context. While we did not observe significant effects in healthy animals, an influence on thrombopoiesis cannot be excluded if TPO levels are significantly elevated, as is the case in patients with thrombocytopenia as a consequence of high dose chemotherapy. 44 Our data also demonstrate that regulation of VEGFR-3 activity in the context of 5-FU treatment can affect thrombopoiesis independently of TPO. Thus a combination of chemotherapy with anti-VEGFR-3 therapy may result in changes in platelet levels not observed with either therapy alone. We note that a number of multi-kinase inhibitors are currently in clinical trials that inhibit VEGFR-3 activation 45 , suggesting that platelet levels should be carefully monitored if combination therapies are attempted. Nevertheless, our data also suggest that megakaryopoiesis is more sensitive to VEGFR-3 activation than VEGFR-3 blockade. In contrast to VEGFR-3 activation via VEGF-C-Cys, which showed significant effects on megakaryocytic differentiation in vitro, as well as in vivo, the administration of VEGFR-3 blocking antibodies significantly affected megakaryopoiesis only in vitro, with the exception that, divergent from our in vitro findings, the administration of VEGFR-3 blocking antibodies to sublethally irradiated mice led to a significant increase of the 2n CD41 + population. This was, however, only seen in comparison with the isotype control, but not with the PBS-treated animals ( Figure 5D ). Also, the polyploid CD41 + population was not affected ( Figure 5D ). Importantly, we used equivalent doses of the mF4-31C1 VEGFR-3 blocking antibody in vivo to those applied in other studies in which the antibody inhibited lymphangiogenesis in experimental animals. 46, 47 These data therefore suggest that blockade of VEGF-3 activity at the minimal doses that suppress lymphangiogenesis are unlikely to elicit side effects on platelet levels.
In summary, we demonstrate here a novel role for VEGFR-3 in regulating the megakaryocytic lineage. Further efforts beyond the scope of this study will focus on elucidating the molecular pathways through which VEGFR-3 activation interfaces with the signalling pathways that control megakaryopoiesis and thrombopoiesis. This will also contribute to our understanding of the physiological and pathophysiological contexts in which VEGFR-3 exerts an effect on megakaryopoiesis.
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